Anxiety DisordersDepressive DisordersTreatment-Resistant Depression (TRD)Chronic PainPalliative & End-of-Life DistressPersonality & Trait Factors

Cancer Healthcare Workers' Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation

This preliminary qualitative study interviewed 12 cancer healthcare professionals and found conditional openness to psychedelic-assisted therapy for advanced cancer, driven by unmet treatment needs and a desire to alleviate suffering. Acceptance was tempered by concerns about safety and risk, with participants emphasising the need for rigorous, well‑designed trials before clinical implementation.

Authors

  • Suresh Muthukumaraswamy
  • Frederick Sundram

Published

International Journal of Environmental Research and Public Health
individual Study

Abstract

Recent clinical trials suggest that psychedelic-assisted therapy is a promising intervention for reducing anxiety and depression and ameliorating existential despair in advanced cancer patients. However, little is known about perceptions toward this treatment from the key gatekeepers to this population. The current study aimed to understand the perceptions of cancer healthcare professionals about the potential use of psychedelic-assisted therapy in advanced cancer patients. Twelve cancer healthcare professionals including doctors, nurses, psychologists and social workers took part in a semi-structured interview which explored their awareness and perceptions toward psychedelic-assisted therapy with advanced cancer patients. Data were analysed using thematic analysis. Four inter-connected themes were identified. Two themes relate to the role and responsibility of being a cancer healthcare worker: (1) ‘beneficence: a need to alleviate the suffering of cancer patients’ and (2) ‘non-maleficence: keeping vulnerable cancer patients safe’, and two themes relate specifically to the potential for psychedelic-assisted therapy as (3) ‘a transformative approach with the potential for real benefit’ but that (4) ‘new frontiers can be risky endeavours’. The findings from this study suggest intrigue and openness in cancer healthcare professionals to the idea of utilising psychedelic-assisted therapy with advanced cancer patients. Openness to the concept appeared to be driven by a lack of current effective treatment options and a desire to alleviate suffering. However, acceptance was tempered by concerns around safety and the importance of conducting rigorous, well-designed trials. The results from this study provide a useful basis for engaging with healthcare professionals about future research, trial design and potential clinical applications.

Available with Blossom Pro

Research Summary of 'Cancer Healthcare Workers' Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation'

Introduction

Advanced-stage cancer is frequently accompanied by psychiatric disorders and broader psychological distress, including treatment-resistant depression, anxiety, existential despair, loss of meaning and desire for a hastened death. Such problems not only reduce quality of life but have been linked to worse physical outcomes, for example increased pain, reduced treatment adherence and higher mortality. Standard pharmacological and psychological treatments show mixed and often limited efficacy in advanced cancer populations, and several meta-analyses have failed to demonstrate clear benefit. In this context, renewed interest in psychedelic-assisted therapy has emerged: classical serotonergic psychedelics such as psilocybin and LSD act at 5-HT2A receptors, have been associated with neural plasticity markers (for example BDNF), and recent small trials in cancer populations have reported rapid and sometimes sustained reductions in depression, anxiety and existential distress. This study aimed to explore how cancer healthcare professionals perceive the potential use of psychedelic-assisted therapy with advanced cancer patients who have depression and/or anxiety. Reynolds and colleagues set out to document awareness, knowledge, attitudes and concerns among clinicians and other cancer care staff, arguing that these professionals are important gatekeepers whose views matter for research translation and future clinical applications. The work is positioned as an initial, qualitative investigation to inform trial design, stakeholder engagement and clinical planning in this emerging field.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (21)

Papers cited by this study that are also in Blossom

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies

Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)

Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers

Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · ACS Pharmacology and Translational Science (2020)

LSD enhances suggestibility in healthy volunteers

Carhart-Harris, R. L., Kaelen, M., Whalley, M. G. et al. · Psychopharmacology (2014)

257 cited
LSD-assisted psychotherapy in patients with terminal cancer

Grof, S., Goodman, L. E., Richards, W. A. · Pharmacopsychiatry (1973)

The peak experience variable in DPT-assisted psychotherapy with cancer patients

Richards, W. A., Rhead, J. C., Dileo, F. B. et al. · Journal of Psychedelic Drugs (1997)

Show all 21 references
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress

Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)

130 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)

423 cited
A Survey of American Psychiatrists’ Attitudes Toward Classic Hallucinogens

Barnett, B. S., Siu, W. O., Pope Jr, H. G. · Journal of Nervous and Mental Disease (2018)

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)

292 cited
Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness

Beaussant, Y., Tulsky, J., Guérin, B. et al. · Journal of Palliative Medicine (2021)

Cited By (2)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.